AUT00063: Clinical Trials

3 trials of AUT00063, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3

Follow AUT00063: new trials by email Literature Review of AUT00063 trials Research Report on AUT00063

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)
AUT00063, Placebo - Hearing Loss, Hearing Impairment
Phase 2CompletedAutifony Therapeutics Limited152016-05-012017-05-24
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss
AUT00063, Placebo - Age-Related Hearing Loss
Phase 2CompletedAutifony Therapeutics Limited782015-01-012018-08-09
Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo
AUT00063, Placebo - Tinnitus, Subjective
Phase 2CompletedAutifony Therapeutics Limited912014-10-012016-03-31

Conditions studied

Hearing Loss (2)  ·  Presbycusis (1)  ·  Tinnitus (1)

Sponsors

Autifony Therapeutics Limited (3)

Countries

United Kingdom (2)  ·  United States (1)

Top investigators

Jaydip Ray, MD (1)  ·  Robert Frisina, PhD (1)  ·  Shakeel R Saeed, MD, FRCS (ORL) (1)

Results publications

PMID 30939361

NIH funding

2015 (1)